Lumida
/ELDN
⌘K
Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc

ELDN
$4.07USD↑+5.99%+0.23 today

MARKET CAP

314.2M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$4 – $4

52W RANGE

$1
$5

AI Summary

Stalk
TrimMedium

The asset remains in a high-confidence Stage 4 decline with a bearish medium-term bias and no mean-reversion support. Price trades below all key EMAs with persistent downward momentum. Until a corrective rally into the 50DMA/200DMA resistance zone and rejection is evident, sales should be deferred. The recommended execution is to Trim into structural rallies rather than aggressive selling into weakness.

  • ↑Phase 2 BESTOW showed Tegoprubart eGFR >70 mL/min vs tacrolimus.
  • ↑Secured $185 M financing; holds ~$56 M cash to fund Phase II through 2023.
  • ↓Reported Q4 net loss $58.4 M; R&D spend rose to $7.3 M.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Eledon Pharmaceuticals (NASDAQ: ELDN) is a biotechnology company that specializes in developing innovative therapies for kidney transplantation and autoimmune diseases, primarily through its lead asset, Tegoprubart. This molecule targets the CD40 pathway and has the potential to serve as a replacement for traditional calcineurin inhibitors (CNIs), which are widely used but associated with significant side effects. Eledon operates in a critical segment of the healthcare market focused on addressing unmet medical needs related to organ transplants and inflammatory conditions, particularly within the increasing demand for kidney transplants.

Bull says

  • ↑Phase 2 BESTOW showed Tegoprubart eGFR >70 mL/min vs tacrolimus.
  • ↑Secured $185 M financing; holds ~$56 M cash to fund Phase II through 2023.
  • ↑Natera partnership validates trial design and transplant community ties.
  • ↑FDA cleared IND for BESTOW, enabling pivotal kidney transplant study.
  • ↑Positive analyst revisions and high interest-rate sensitivity support upside.
  • ↑U.S. kidney transplant market (~25 K/year) underpins long-term growth.

Bear says

  • ↓Reported Q4 net loss $58.4 M; R&D spend rose to $7.3 M.
  • ↓Cash runway under 12 months despite recent capital raise.
  • ↓Concurrent trials risk enrollment delays; transplant enrollment uneven.
  • ↓Established CNIs and large biotech rivals may hinder adoption.
  • ↓Weak earnings yield and high short interest signal skepticism.
  • ↓Additional funding needed for ALS program adds dilution risk.

Earnings Call · Q2 2022 · Mgmt. Guidance

Updated 06-28-2026neutral

Transcript signals

Bull points

  • As of June 30, 2022, Elladon had $70.5 million in cash and cash equivalents, which we expect to be sufficient to fund our clinical trial operations as currently planned into 2024.
  • Our cash runway allows us to initiate the phase two trial of Tegel-Pubart for the prevention of organ rejection in patients receiving a kidney transplant.
  • As of June 30, 2022, Elladon had $70.5 million in cash and cash equivalents, which we expect to be sufficient to fund our clinical trial operations as currently planned into 2024.

Bear points

  • The company reported a net loss of $9.2 million, or $0.65 per share, for the three months into June 30, 2022, compared to a net loss of $7.4 million, or $0.50, for the same period in 2021.
  • Research and development expenses were $5.7 million for the three months into June 30, 2022, compared to $4.2 million for the comparable period in 2021, which was an increase of $1.5 million.
  • But additional financing will be required to fund any future ALS clinical trials.
Read full transcript analysis ›